Citadel Advisors’s Amphastar Pharmaceuticals AMPH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$390K Buy
19,900
+7,600
+62% +$186K ﹤0.01% 9871
2025
Q4
$329K Sell
12,300
-2,800
-19% -$72.1K ﹤0.01% 9941
2025
Q3
$402K Sell
15,100
-3,200
-17% -$82.6K ﹤0.01% 9655
2025
Q2
$420K Sell
18,300
-2,500
-12% -$62K ﹤0.01% 9035
2025
Q1
$603K Buy
20,800
+8,600
+70% +$275K ﹤0.01% 8069
2024
Q4
$453K Sell
12,200
-12,400
-50% -$567K ﹤0.01% 8780
2024
Q3
$1.19M Buy
24,600
+17,200
+232% +$755K ﹤0.01% 6506
2024
Q2
$296K Sell
7,400
-7,500
-50% -$311K ﹤0.01% 9167
2024
Q1
$654K Buy
14,900
+3,600
+32% +$186K ﹤0.01% 7803
2023
Q4
$699K Buy
11,300
+2,100
+23% +$110K ﹤0.01% 7402
2023
Q3
$423K Buy
9,200
+2,300
+33% +$125K ﹤0.01% 8429
2023
Q2
$397K Buy
6,900
+1,200
+21% +$53.2K ﹤0.01% 8429
2023
Q1
$214K Sell
5,700
-2,400
-30% -$78.7K ﹤0.01% 10072
2022
Q4
$227K Sell
8,100
-13,100
-62% -$380K ﹤0.01% 9890
2022
Q3
$596K Sell
21,200
-12,200
-37% -$398K ﹤0.01% 8075
2022
Q2
$1.16M Buy
33,400
+19,400
+139% +$692K ﹤0.01% 6684
2022
Q1
$503K Buy
+14,000
New +$397K ﹤0.01% 9379
2019
Q2
Sell
-10,800
Closed -$221K 9113
2019
Q1
$221K Buy
+10,800
New +$242K ﹤0.01% 8071
2016
Q1
Sell
-300
Closed -$4K 6681
2015
Q4
$4K Buy
+300
New +$3.96K ﹤0.01% 8480
2015
Q3
Sell
-2,100
Closed -$37K 8846
2015
Q2
$37K Buy
+2,100
New +$32.7K ﹤0.01% 7855

Other funds holding AMPH

Citadel Advisors's AMPH Position: Q1 2026 in Review

Citadel Advisors reduced its Amphastar Pharmaceuticals (AMPH) stake by 71% in Q1 2026, selling an estimated $3.99M and leaving 65,540 shares worth $1.28M. The position accounts for ﹤0.01% of the portfolio, ranked #7109.

Citadel Advisors first reported a position in AMPH in Q3 2014 and has held it in 40 quarters since. The position peaked at $10.5M in Q2 2024. 215 funds tracked by Wall St. Rank hold AMPH as of Q1 2026.

  • Citadel Advisors held 65,540 shares of Amphastar Pharmaceuticals worth $1.28M as of Q1 2026.
  • Citadel Advisors sold 163,184 Amphastar Pharmaceuticals shares in Q1 2026, an estimated $3.99M.
  • Amphastar Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #7109 holding.
  • Citadel Advisors first reported a position in Amphastar Pharmaceuticals in Q3 2014 and has held it in 40 quarters since.
  • Citadel Advisors's Amphastar Pharmaceuticals position peaked at $10.5M in Q2 2024.
  • 215 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.